ReviewBiomedical engineering online2025
The future of vesicular drug delivery: transferosomes in therapeutic advancement-applications, innovations and challenges.
Review in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Toxicity of nanostructures in drug delivery applications.Pharmaceutical science advances · 2026Review
- Liposomal Morin Attenuates DMH-Associated Colonic Oxidative Stress, Inflammation, and Apoptosis/Autophagy-Related Dysregulation in Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Skin Barrier-Informed Topical and Transdermal Drug Delivery: Excipient-Driven Strategies, Vehicle Transformation, and Translational Challenges.Pharmaceutics · 2026Review
- Lipid-based nanocarriers for antifungal drug delivery.Discover nano · 2026Review
- Transferosomes as Drug Delivery Systems: Design Principles, Deformability, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- CT-based habitat analysis combined with multi-channel deep learning for predicting early recurrence after pancreatic cancer resection: a multicenter study.Journal of translational medicine · 2026Article
- Hybrid GAN-LSTM framework for diabetic foot ulcer image synthesis and automated diagnosis.Frontiers in medicine · 2026Article
- Metabolomics identifies chenodeoxycholic acid as a protective factor in diabetic foot ulcers.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transferosomes represent a novel vesicular drug delivery system developed to overcome the limitations of traditional transdermal systems. These ultra-deformable lipid bilayers facilitate barrier disruption via diffusion across the stratum corneum and transport both small molecules and macromolecules such as proteins and peptides. This review discusses the structural components of transferosomes, methods of preparation and methods of characterization, with an emphasis on the unique mechanism of skin penetration that is initiated by a trans-epidermal hydration gradient. The potential applications for transferosomes span a wide range of therapeutics including antioxidants, corticosteroids, anticancer agents, NSAIDs and biomolecules, such as insulin and interferons. Transferosomes offer many benefits such as enhanced bioavailability, reduced systemic effects, regional action, and improved patient adherence. However, the leap to clinical applications has been challenging due to barriers related to stability, scalability, complex formulations, variability in skin biology and toxicity. Recent innovations-hybrid vesicular systems, polymer-coated transferosomes and lyophilization to improve stability or laden transferosomes with topical cosmeceuticals and neurotherapeutics-are examples of a more novel therapeutic approach to help patients. Future directions may involve stimuli-responsive systems, buccal and intranasal delivery, and microneedle arrays or a personalized medicine model. In sum, transferosomes represent a flexible nanocarrier platform that has the potential to change transdermal and mucosal drug delivery through an integrated approach between pharmaceutical and biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.